🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
NATCO Pharma Limited (BOM:524816)
India flag India · Delayed Price · Currency is INR
817.00
-4.50 (-0.55%)
At close: Nov 20, 2026

NATCO Pharma Statistics

Total Valuation

NATCO Pharma has a market cap or net worth of INR 159.74 billion. The enterprise value is 154.90 billion.

Market Cap159.74B
Enterprise Value 154.90B

Important Dates

The last earnings date was Friday, November 13, 2026.

Earnings Date Nov 13, 2026
Ex-Dividend Date Nov 19, 2026

Share Statistics

Current Share Class 196.17M
Shares Outstanding n/a
Shares Change (YoY) -0.00%
Shares Change (QoQ) +0.02%
Owned by Insiders (%) 26.77%
Owned by Institutions (%) 11.51%
Float 100.88M

Valuation Ratios

The trailing PE ratio is 17.66 and the forward PE ratio is 19.20.

PE Ratio 17.66
Forward PE 19.20
PS Ratio 5.17
PB Ratio 1.64
P/TBV Ratio 1.68
P/FCF Ratio 68.82
P/OCF Ratio 21.51
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.94, with an EV/FCF ratio of 66.74.

EV / Earnings 18.70
EV / Sales 5.01
EV / EBITDA 16.94
EV / EBIT 21.32
EV / FCF 66.74

Financial Position

The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.11.

Current Ratio 2.17
Quick Ratio 1.19
Debt / Equity 0.11
Debt / EBITDA 1.37
Debt / FCF 4.45
Interest Coverage 14.49

Financial Efficiency

Return on equity (ROE) is 9.01% and return on invested capital (ROIC) is 6.15%.

Return on Equity (ROE) 9.01%
Return on Assets (ROA) 7.45%
Return on Invested Capital (ROIC) 6.15%
Return on Capital Employed (ROCE) 5.75%
Weighted Average Cost of Capital (WACC) n/a
Revenue Per Employee 6.98M
Profits Per Employee 1.87M
Employee Count4,433
Asset Turnover 0.28
Inventory Turnover 0.73

Taxes

In the past 12 months, NATCO Pharma has paid 647.00 million in taxes.

Income Tax 647.00M
Effective Tax Rate 7.24%

Stock Price Statistics

The stock price has decreased by -1.58% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -1.58%
50-Day Moving Average 808.10
200-Day Moving Average 926.16
Relative Strength Index (RSI) 55.85
Average Volume (20 Days) 82,299

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, NATCO Pharma had revenue of INR 30.92 billion and earned 8.29 billion in profits. Earnings per share was 46.26.

Revenue30.92B
Gross Profit 24.30B
Operating Income 5.66B
Pretax Income 8.94B
Net Income 8.29B
EBITDA 7.51B
EBIT 5.66B
Earnings Per Share (EPS) 46.26
Full Income Statement

Balance Sheet

The company has 15.17 billion in cash and 10.33 billion in debt, with a net cash position of 4.84 billion.

Cash & Cash Equivalents 15.17B
Total Debt 10.33B
Net Cash 4.84B
Net Cash Per Share n/a
Equity (Book Value) 97.65B
Book Value Per Share 545.11
Working Capital 22.85B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.43 billion and capital expenditures -5.11 billion, giving a free cash flow of 2.32 billion.

Operating Cash Flow 7.43B
Capital Expenditures -5.11B
Depreciation & Amortization 1.84B
Net Borrowing 7.64B
Free Cash Flow 2.32B
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 78.56%, with operating and profit margins of 18.32% and 26.79%.

Gross Margin 78.56%
Operating Margin 18.32%
Pretax Margin 28.91%
Profit Margin 26.79%
EBITDA Margin 24.27%
EBIT Margin 18.32%
FCF Margin 7.51%

Dividends & Yields

This stock pays an annual dividend of 4.25, which amounts to a dividend yield of 0.52%.

Dividend Per Share 4.25
Dividend Yield 0.52%
Dividend Growth (YoY) 21.43%
Years of Dividend Growth n/a
Payout Ratio 9.79%
FCF Payout Ratio n/a
Buyback Yield 0.00%
Shareholder Yield 0.52%
Earnings Yield 5.66%
FCF Yield 1.45%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Analyst Forecast

The average price target for NATCO Pharma is 1,002.11, which is 22.66% higher than the current price. The consensus rating is "Buy".

Price Target 1,002.11
Price Target Difference 22.66%
Analyst Consensus Buy
Analyst Count 11
Revenue Growth Forecast (3Y) 2.09%
EPS Growth Forecast (3Y) -10.62%

Stock Splits

The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.

Last Split Date Nov 26, 2015
Split Type Forward
Split Ratio 5

Scores

Altman Z-Score n/a
Piotroski F-Score 3